Danazol

Danazol inhibits the proliferation of cancer cell MDA-MB-231 and MCF-7 with IC50 of 65 µg/mL and 31 µg/mL. Danazol arrests the cell cycle at G1 phase, induces apoptosis in MDA-MB-231 through PKCα signaling pathway[1].

Product Specifications

CAS Number

[17230-88-5]

UNSPSC

12352005

Hazard Statement

H312+H332, H361

Target

Apoptosis; PKC; Tyrosinase

Type

Reference compound

Related Pathways

Apoptosis; Epigenetics; Metabolic Enzyme/Protease; TGF-beta/Smad

Field of Research

Cancer; Endocrinology

Assay Protocol

https://www.medchemexpress.com/Danazol.html

Purity

99.70

Solubility

DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C) |Ethanol : 20 mg/mL (ultrasonic)

Smiles

C#C[C@]1(O)CC[C@@]2([H])[C@]3([H])CCC4=CC5=C(C=NO5)C[C@]4(C)[C@@]3([H])CC[C@@]21C

Molecular Formula

C22H27NO2

Molecular Weight

337.46

Precautions

H312+H332, H361

References & Citations

[1]Thomas GW, et al., Effects of danazol on endothelial cell function and angiogenesis. Fertil Steril. 2007 Oct;88 (4 Suppl) :1065-70.|[2]Chang TS, Lin JJ. Inhibitory effect of danazol on melanogenesis in mouse B16 melanoma cells. Arch Pharm Res. 2010 Dec;33 (12) :1959-65. |[3]Deka SJ, et al., Danazol has potential to cause PKC translocation, cell cycle dysregulation, and apoptosis in breast cancer cells. Chem Biol Drug Des. 2017 Jun;89 (6) :953-963.